Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Pinteon Therapeutics General Information
PNT001, their lead antibody, completed a Phase 1 safety study in healthy adults showing it was well-tolerated at doses that may provide therapeutic effect. A Phase 1 study in acute traumatic brain injury was terminated for non-safety reasons after enrolling only one patient. The company had planned a Phase 1b/Phase 2 study in Alzheimer's disease patients by the end of 2021.
Contact Information
Primary Industry
Biotech
Corporate Office
Newton Center, Massachusetts
United States
United States
Drug Pipeline
PNT001
Phase 1Key Partnerships
Advanced Technology International (ATI), U.S. Department of Defense
Pinteon Therapeutics Funding
No funding data available
To view Pinteon Therapeutics's complete valuation and funding history, request access »